Diffuse large B cell lymphoma classification: Difference between revisions
Jump to navigation
Jump to search
Mohamed riad (talk | contribs) |
Mohamed riad (talk | contribs) |
||
| Line 45: | Line 45: | ||
*'''Primary Cutaneous DLBCL, Leg type (rare)''' | *'''Primary Cutaneous DLBCL, Leg type (rare)''' | ||
*Typically ABC subtype; frequent mutation of [[MYD88]]; distinguish from other [[Skin|cutaneous]] [[B-cell lymphoma]] | *Typically ABC subtype; frequent mutation of [[MYD88]]; distinguish from other [[Skin|cutaneous]] [[B-cell lymphoma]] | ||
*Typically in elderly patients and women; presents with [[skin nodules]] in lower [[Leg|legs]]; 10–15% of cases arise in other sites; poor [[prognosis]] | *Typically in elderly patients and women; presents with [[skin nodules]] in lower [[Leg|legs]]; 10–15% of cases arise in other sites; poor [[prognosis]] | ||
* | * | ||
*'''EBV-positive diffuse large B-cell lymphoma, NOS (rare)''' | *'''EBV-positive diffuse large B-cell lymphoma, NOS (rare)''' | ||
Revision as of 16:16, 16 April 2021
|
Diffuse large B cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diffuse large B cell lymphoma classification On the Web |
|
American Roentgen Ray Society Images of Diffuse large B cell lymphoma classification |
|
Directions to Hospitals Treating Diffuse large B cell lymphoma |
|
Risk calculators and risk factors for Diffuse large B cell lymphoma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2] Anila Hussain, MD [3]
Overview
Diffuse large B cell lymphoma may be classified based on location into nodal and extranodal disease and based on pathological and clinical features.
Classification
Classification Based on Location
Diffuse large B cell lymphoma may be classified based on location:
- Nodal disease
- Extranodal disease
Classification Based on Pathological and Clinical Features
According to the updated WHO classification, diffuse large B cell lymphoma may be classified based on pathological and clinical features into the following:
Diffuse large B cell lymphoma, not otherwise specified
- Diffuse large B-cell lymphoma, NOS (represents more than 80% of cases of large B-cell lymphomas)
- Molecular subtypes: GCB subtype, about 60%; ABC subtype, about 25–30%; unclassifiable, about 10–15%; new molecular entities recently characterized
Diagnostic features
Diffuse proliferation of medium or large lymphoid B cells typically expressing CD19, CD20, CD22, CD79a, PAX5, and surface or cytoplasmic immunoglobulin; molecular techniques (e.g., GEP) or IHC-based algorithms recommended to classify subtypes
Clinical Features and Outcome
- The median age is 65–70 yr
- Nodal presentation is the most common and 30–40% of cases are primary extranodal
- prognosis is variable
Other Large B Cell Lymphoma (DLBCL) type
- T-cell/histiocyte-rich large B cell lymphoma (rare)
- Few large B cells embedded in a background of T cells and histiocytes; distinguish from nodular lymphocyte-predominant Hodgkin lymphoma
- Commonly found in middle-aged men, advanced stage with extranodal involvement (liver, spleen, bone marrow); poor prognosis
- Primary diffuse large B cell lymphoma of the central nervous system (rare)
- Typically ABC subtype; frequent loss of HLA class I/II; frequent mutation of MYD88
- Exclusively in CNS or intraocular region, rare systemic involvement; poor prognosis; specialized treatment with CNS-penetrating agents, with or without radiation therapy, required; targeted therapies under investigation
- Primary Cutaneous DLBCL, Leg type (rare)
- Typically ABC subtype; frequent mutation of MYD88; distinguish from other cutaneous B-cell lymphoma
- Typically in elderly patients and women; presents with skin nodules in lower legs; 10–15% of cases arise in other sites; poor prognosis
- EBV-positive diffuse large B-cell lymphoma, NOS (rare)
- Variable histologic features, including Hodgkin-like lesions, monomorphic to polymorphic patterns; EBV detectable in tumor and frequently in serum
- Typically in patients older than 50 yr; more frequent in Asia and Latin America than elsewhere; extranodal involvement common; prognosis varies
- EBV-positive mucocutaneous ulcer (rare)
- Polymorphic infiltrate with frequent Hodgkin-like cells; EBV is detectable in tumor
- Presents as localized, ulcerated lesions in oral mucosa, intestine, or skin; dissemination is rare; commonly occurs as iatrogenic or age-related disease in immunocompromised patients; favorable prognosis; consider reduction of immunosuppressive therapy
- Diffuse large B-cell lymphoma associated with chronic inflammation (rare)
- Morphologically similar to DLBCL, NOS but strongly associated with EBV; also called pyothorax-associated lymphoma, when associated with chronic pyothorax
- Occurs in context of chronic inflammation, involving pleural cavity or other sites such as bone and joints; male predominance; poor prognosis
- Lymphomatoid granulomatosis (rare)
- EBV-driven angiocentric and angiodestructive lymphoproliferation with reactive T cells; grade based on proportion of EBV positive B cells and cytologic features
- Commonly involves extranodal sites (lung >90%); often in context of immunodeficiency; prognosis varies; no standard therapy
- Large B-cell lymphoma with IRF4 rearrangement (rare)
- Strong expression of IRF4/MUM1, usually with IRF4 rearrangement; diffuse-to-follicular morphologic features; distinguish from pediatric-type follicular lymphoma
- Commonly in children and young adults; typically involves Waldeyer’s ring or cervical lymph nodes; favorable prognosis
- Primary mediastinal (thymic) large B-cell lymphoma (around 6% of large B-cell cases)
- Putative thymic B-cell origin; medium-to-large B cells, frequently with sclerosis; distinctive phenotype (CD30, CD23, PDL1, PDL2) and unique GEP signature; frequent 9p21 amplification, genomic alterations of CIITA
- Typically in young adults, female predominance; mediastinal prominence with local invasion; can involve other nodal or extranodal sites (kidney and liver); prognosis varies; DA-EPOCH-R an option
- Intravascular large B-cell lymphoma (rare)
- Lymphoma cells exclusively within lumina of small or intermediate vessels; bone marrow and skin biopsy may be useful to establish diagnosis
- Wide intravascular dissemination (lung, bone marrow, skin, CNS, kidney), often associated with fever of unknown origin or neurologic or cutaneous symptoms; poor prognosis
- ALK-positive large B-cell lymphoma (rare)
- ALK-positive large B cells, immunoblastic features and plasma cell phenotype, typically CD20-negative
- Typically in young men with generalized lymphadenopathy; prognosis varies
- Plasmablastic lymphoma (rare)
- Immunoblastic or plasmablastic B cells, plasma-cell phenotype (CD138-positive, CD20-negative), often EBV-positive; distinguish from multiple myeloma
- Often associated with HIV infection or immunosuppression; frequently extranodal; poor prognosis; consider more intensive regimens
- HHV8-positive diffuse large B-cell lymphoma (rare)
- HHV8-positive IgM lambda plasmablasts; often associated with HHV8-positive multicentric Castleman disease
- Often associated with HIV infection; lymphadenopathy and splenomegaly are common; poor prognosis; no standard therapy
- Primary effusion lymphoma (rare)
- Immunoblastic or plasmablastic B cells, HHV8-positive and usually EBV-positive; plasma-cell phenotype lacking usual B-cell markers; CD20-negative
- Often associated with HIV infection or immunosuppression; presents as pleural, pericardial, or peritoneal serous effusions, often without detectable tumor mass; poor prognosis; DA-EPOCH an option
- High-grade B-cell lymphoma
- High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements or both (doublehit or triple-hit lymphoma) (4–8% of large B-cell cases)
- Variable morphology, including DLBCL, B-cell lymphoma unclassifiable (with features intermediate between DLBCL and Burkitt lymphoma), and blastoid features; MYC and BCL2 and/or BCL6 rearrangements, detected by FISH
- Frequently aggressive clinical presentation; higher risk of CNS involvement; poor prognosis; consider more intensive immunochemotherapy regimens, such as DA-EPOCH-R
- High-grade B-cell lymphoma, NOS (rare)
- Heterogeneous category; often has morphologic features intermediate between DLBCL and Burkitt lymphoma; lacks MYC and BCL2 and/or BCL6 rearrangements
- Frequently aggressive clinical presentation; increased risk of CNS involvement; poor prognosis; consider more intensive immunochemotherapy regimens
- B-cell lymphoma, unclassifiable
- B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma (grey-zone lymphoma) (rare)
- Overlapping morphologic or immunophenotypic features, or both, between DLBCL and classic Hodgkin lymphoma
- Male predominance, younger age (20–40 yr); mediastinal presentation most common (80% of cases) but can occur in other sites; prognosis varies; no standard therapy, consider therapy suitable for DLBCL or Hodgkin lymphoma